Tags Posts tagged with "$EAPH"

$EAPH

0 1156

Easton Pharmaceuticals Provides Update on Its Medicated Markets Partnership, Joint Initiatives and the Booming Medical Marijuana Climate in California for January 2015

HUMBOLDT, CA and TORONTO, ON–(Marketwired – Feb 9, 2015) – Easton Pharmaceuticals Inc (OTC PINK: EAPH) Provides Medicated Markets partnership update, discloses joint initiatives and provides comments and opinions on the booming medical marijuana climate in California in January 2015

Easton announced its intention and formally entered the lucrative medical marijuana industry in the United States through its 40% ownership purchase of Medicated Markets International LLC, a major Medical Marijuana grower in the state of California. Medicated Markets International’s main business directive is the cultivation of marijuana for wholesale, in the state of California and other Legalized states. 100% of its current sales volume is sold in the State of California. As such wholesale price movements in Medical Marijuana rates in California directly impact Medicated Market’s bottom line.

In January wholesale prices in California for prices paid by current dispensaries serviced have risen an average of 15% depending on the strain. The average wholesale price sold by Medicated Markets in December 2014 was USD$1925 per pound while January 2015 prices averaged USD$2185 per pound. The rise in price is partly due to seasonal demand as well as the current robust nature of demand in California.

Medicated Markets maintains current operations in multiple counties in California, including Riverside County and Humboldt County (20 acres), with additional property to be slated in Mendocino County in the range of approximately 30 acre’s (outdoor greenhouse). This property should be in escrow by late February and close by March, an update on that specific detail will be provided once the property is in escrow. The reason Medicated Markets has diversified into multiple counties has been to remove dependence on any one counties restrictions on water use, as well as to guard against any single counties potential future ordinance changes. Two Master Growers for Medicated Markets LLC and their verifiable license numbers and addresses locations are stated below.

Mr. Miguel G Garcia #330471333 verifiable at http://mmic.cdph.ca.gov 22345 Comet Crt, Perris CA 92570

Mr. Matthew A Woods #081601791054518 http://verify.greenlifemedical.com 22945 Deprad St, Perris CA 92570

The locations listed above are currently active growing sites for nursery and strain development maintained by the master growers listed.

Revenue estimates for Medicated Markets facilities fiscal 2015 should be ready for presentation and disclosure on Monday February 16th; with details including exact strains planted this season, and harvest time lines. Questions related to current business posted toinfo@medicatedmarkets.com will also be answered. All questions need to be submitted by end of day Tuesday February 10th 2015 to be considered.

In other developments, a case involving a group of patients who allege that Health Canada’s MMPR program violates the constitution will begin trial on February 23, 2015. The case is being led by B.C. lawyer John Conroy and challenges rules set out by the government’s revamped medical marijuana program, including the ban on home grown marijuana and Marijuana products such as edibles and extracts. As Easton Pharmaceuticals Inc wish’s to develop site delivery of Marijuana product, and extracts for medicinal purposes in Canada and such maintains a vested interest in the outcome of these hearings.

Easton Pharmaceuticals, along with its partners, Medicated Markets International LLC is continually searching for synergistic opportunities to add to its current portfolio of Medical Marijuana related investments In US markets as well as Canadian and encourages communication with any and all interested parties.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs to treat cancer and other conditions that are in various stages of development with 3 of its OTC products to soon be ready for marketing and sale. Easton has completed an acquisition that grants a 40% ownership interest in Medicated Markets International LLC; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system, and has an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada, located in Ontario, Canada which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope,” “positive,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

1 1347

Easton Pharmaceuticals Releases December Vaporizer Sales, Highlighting a 62% Month Over Month Increase in Revenues on Fiscal 2014 Vaporizer Segment Revenues

NEW YORK, NY–(Marketwired – Feb 5, 2015) – Easton Pharmaceuticals (OTC PINK: EAPH) announces December Vaporizer sales highlighting a 62% month over month increase in revenues as it relates to www.ecigmarkets.com, a wholly owned Vaporizer unit of Easton Pharmaceuticals Inc.

The Vaporizer business showed a month over month increase with sales of $41,789.94 for the month of December. A 61% increase in sales from the prior month’s sales of $25,638.00 in November 2014. Gross margins averaged 55% for December 2014 mainly due to lack of discounting. Increase in sales attributable to rise in associated SEO marketing campaigns. Total sales since inception of vaporizer business lines in fiscal 2014, have directly resulted in $67,428.94 in gross revenues. Month end Vaporizer inventory on hand was shown to be $4,956.00.

Currently the most popular brand has been the following unit, and as such Easton plans to expand its relationship with Davinci vaporizers in the coming days:
http://ecigmarkets.com/product/davinci-vaporizer/

The DaVinci Vaporizer combines a feature rich platform with rugged portability. Our most popular model in the DaVinci line, which is offered in a very appealing and popular black matte finish.

Medicated Markets has updated its website www.medicatedmarkets.com as well as included updates on its current cloning efforts on its twitter feed https://twitter.com/medimarkets. Many shareholders have requested revenue estimates as it relates to Easton / Medicated Markets partnership venture. Those numbers are expected to not be available for at least 1 more week until all clones have shown proper rooting progress. An update on current wholesale marijuana pricing in California as it relates to current dispensary partners should also be forthcoming by early next week.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and other industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns an interest in a topically-delivered cancer drug and other OTC therapeutic products that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
www.medicatedmarkets.com

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

0 1254

Easton Pharmaceuticals Discloses List of Joint Initiatives With Medicated Markets International LLC, Its California Based Medical Marijuana Partner

TORONTO, ON–(Marketwired – Jan 28, 2015) –  Easton Pharmaceuticals Inc. (OTC:EAPH) Announces list of joint initiatives with Medicated Markets International LLC, it’s California based medical marijuana partner.

Easton would like to provide further details and answers to questions posed to the company regarding current partnership aspirations shared with Medicated Markets International LLC, which includes expectations and future endeavours in both the US and Canadian medical marijuana markets.

Medicated Markets is currently narrowing down options for additional land purchases in Mendocino, California as well as Trinity County for an upgraded greenhouse facility build out. This joint venture initiative and land purchase timeline is set to complete sometime in the early spring.

Medicated Markets has also decided to enter the Toronto, Canada Medical Marijuana Market by setting up a dispensary location and allowing patients greater access to their medicinal needs. Medicated Markets has recently completed all preliminary due diligence on a dispensary and distribution site in Canada for Medical Marijuana. Currently Medicated Markets is actively searching for a retail location in the Greater Toronto Area. Co-distribution with current MMPR approved Health Canada Licensed Providers are in the initial stages of discussion but are fast moving and as such no additional details can be disclosed at this time.

Johnny Martinez, President of Medicated Markets, stated, “Our goals for this venture is much larger than joint dispensary locations in Toronto, Canada. We want to develop a topical patch and Gel delivery formulation to compete with other mouth spray type products currently available in the market as treatment. Topical Medical Marijuana for target site treatment of pain, skin and bone related medicinal use has been seen as an effective alternative to inhalation through the lungs.”

American Academy of Pediatrics (AAP) also recognized marijuana may be a treatment option for kids suffering with “life-limiting or severely debilitating conditions for whom current therapies are inadequate.” This pediatricians group will now suggest that the federal government change marijuana from a Schedule I illegal drug (where it’s classified alongside heroin) to a Schedule II controlled substance, Levy stated. The U.S. Drug Enforcement Administration lists Adderall or Ritalin as examples of Schedule II drugs. We now believe rescheduling of Medical marijuana is imminent in US jurisdictions.

On January 20th 2015 Easton Pharmaceuticals had announced a stock swap agreement with Medicated Markets International LLC and has allocated 200 Million restricted shares of Easton’s common stock to be held in escrow, as per agreement. In addition, payment of $100,000 has been wired to Medicated Markets and receipt of funds has been confirmed.

All responsibilities and liabilities with respect towards the medical marijuana business in California resides with Medicated Markets International. Easton is pleased and is confident it has partnered with knowledgeable and reputable company in Medicated Markets who share the same goal of moving the medical marijuana industry in both the United States and Canada successfully forward.

Medical cannabis is commonly used to self-treat, although not limited, severe pain associated with Cancer, arthritis, and musculoskeletal pain. As of June 2014, estimates from the office of Information Commissioner of Canada list “severe arthritis” as the reason that 65% of Canadians who are allowed to possess and use marijuana for medicinal purposes. Proposed initiative addresses site transmission of Transdermal marijuana extract to the site of the pain, without having to inhale through the lungs. Currently McGill University, McMaster University, and University of Guelph have research projects into Medical Marijuana in Canada.

The Medical Marijuana Movement in North America started in California, which was the first state to establish a medical marijuana program, enacted by Proposition 215 in 1996 and Senate Bill 420 in 2003. Prop. 215, also known as the Compassionate Use Act, was approved by an initiative with a 55% majority, allowing people with cancer, AIDS and other chronic illnesses the right to grow or obtain marijuana for medical purposes when recommended by a doctor. SB 420, or the Medical Marijuana Protection Act, was signed into law by Governor Gray Davis and established an identification card system for medical marijuana patients. Marijuana advocates are hopeful that if they can get a legalization measure on the ballot in California in 2016, it will pass and federal reform will follow shortly afterwards.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and other conditions that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Ontario, which has also received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

http://ecigmarkets.com/

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

1 1720

Easton Pharmaceuticals Inc Is Pleased to Announce Definitive Finalized Agreement With Medicated Markets International LLC, a Major California Based Medical Marijuana Grower

TORONTO, ON–(Marketwired – Jan 20, 2015) – Easton Pharmaceuticals Inc. (OTC: EAPH) Signs Finalized agreement with Medicated Markets International LLC., a major California medical marijuana grower in a restricted share swap agreement. Up to 25% of Easton restricted stock, rights to use Easton’s transdermal matrix technologies, and One hundred thousand dollars; to be exchanged for 40% of Medicated Markets International LLC.

Easton Pharmaceuticals has been searching to enter the highly Lucrative Medical Marijuana Grower market within legalized jurisdictions. Medicated Markets International LLC, is a current grower / cultivator located in the City of Perris, California, (20 acres) Riverside county and one main growing location in Mendocino County, California with a total actual growing area of approximately 3 acres. Medicated Markets has been looking to buy assets in Canada, including submission of their own MMPR application to Health Canada, or by buying a controlling interest in an already Licensed Provider. A growing US economy as well as strong Medical Marijuana demand In California, while Canadian assets have been falling has made this opportunity and agreement to be a great benefit for both companys.

The recent sharp drop in the Canadian Dollar was also a driving factor in the completion of this deal, as Canadian assets have become much more attractive at discounted rates in US Dollar terms. Easton’s US partners have shown great interest in diversifying through Joint venture operations in Canada centered on patient acquisition as well as transdermal medication delivery and associated product launch. Details on these initiatives in both US and Canadian markets should be ready for disclosure by early next week. The two Medicated Markets Califiornia Master grower License numbers are #B8377788, and #330471333. More pictures of current mother plants used for cloning, dispensary cash receipts as well as grow location addresses will be available at https://twitter.com/medimarkets in the coming days.

Medical cannabis is commonly used to self-treat severe pain associated with Cancer, arthritis, musculoskeletal pain and other ailments. As of June 2014, estimates from the office of Information Commissioner of Canada list “severe arthritis” as the main reason 65% of Canadians are possessing marijuana for medicinal purposes. Proposed initiatives hope to eventually allow the transdermal delivery of medicinal marijuana to a patient’s area of pain, without having to inhale through the lungs. Currently McGill University, McMaster University, and University of Guelph have ongoing research projects into Medical Marijuana in Canada.

The Medical Marijuana Movement in North America started in California, which was the first state to establish a medical marijuana program, enacted by Proposition 215 in 1996 and Senate Bill 420 in 2003. Prop. 215, also known as the Compassionate Use Act, was approved by an initiative with a 55% majority, allowing people with cancer, AIDS and other chronic illnesses the right to grow or obtain marijuana for medical purposes when recommended by a doctor. SB 420, or the Medical Marijuana Protection Act, was signed into law by Governor Gray Davis and established an identification card system for medical marijuana patients. Marijuana advocates are hopeful that if they can get a legalization measure on the ballot in California in 2016, it will pass and federal reform will follow shortly afterwards.

About Easton Pharmaceuticals

Related Quotes

  • Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs to treat cancer and other conditions that are in various stages of development with 3 of its OTC products to soon be ready for marketing and sale. Easton has completed an acquisition that grants a 40% ownership interest in Medicated Markets International LLC; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada, located in Ontario, Canada which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

1 1249

Easton Pharmaceuticals Provides Medicated Markets Due Diligence Update With the Disclosure of Total Number of Plants, Strains and Dispensaries Currently Being Serviced

TORONTO, ON–(Marketwired – Jan 12, 2015) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces due diligence update with the disclosure of total number of plants, strains and current dispensaries being serviced.

With the company’s quest to provide as much detailed information as possible with its negotiations as previously announced, the company is pleased to share some invoices on current medicated markets dispensaries who are its current clients, this update is as promised and was following Eastons meetings with Medicated Markets and Its Master Grower over this past weekend In Toronto, Canada.

Medicated Markets possesses California Marijuana grower’s licenses and are currently growing at its two Nursery locations (20 acre’s) in City of Perris, Riverside County, California and one main growing location in Mendocino County, California with a total actual growing area of approximately 3 acres and a total plant volume of 10,000 plants. Capacity could be raised quite easily as plants require approximately 4 square feet of growing area. Each plant is expected to yield anywhere from 1 to 2 pounds of medicinal grade Marijuana.

Pictures of the mother plants that are used for cloning and copies of sales invoices for the corresponding dispensaries can be found immediately at @Medimarkets orhttps://twitter.com/medimarkets with indexing to their http://medicatedmarkets.com/ website once its delegation returns from Toronto on the 18th of January 2015.

A sampling of Current Dispensaries being serviced by growers at Medicated Markets are:

Herban Life
1820 Mentone Blvd. Suite A
Mentone, CA 92539

SBPC
154 South E. Street
San Bernadino, CA 92401

Doc Holiday’s
1366 North E. Street
San Bernadino, CA 92405

Dr. Green Thumb’s
6645 Lankershim Blvd
North Hollywood, CA 91606

Smokes “N” Puffs

1743 West foothill blvd
Upland, CA 91786

DNR
1911 Mentone Blvd
Mentone, CA 92359

A few of the medicated markets strains being grown and a few of the ones in the current seed bank with mother’s pending are as follows:

1. AK47 (mostly Sativa) AK-47 mixes Colombian, Mexican, Thai, and Afghani varieties, bringing together a complex blend of flavors and effects. While AK-47’s scent is sour and earthy, its sweet floral notes can only be fully realized in the taste.
Awards:
- 3rd place Hybrid Cup at the 2011 High Times Cannabis Cup
– 2nd place Sativa Cup at the 1999 High Times Cannabis Cup
– 2nd place Indica Cup at the 2003 High Times Cannabis Cup
– 1st place Sativa Cup at the 2010 Treating Yourself Expo

2. Chocolope (95% Sativa, 5% Indica)
Awards
- 2nd Place Sativa Cup at the 2010 High Times Cannabis Cup.
– 2nd Place Outdoor Cup at the Spannabis 2011 Champions Cup.
– 3rd Place Indoor Bio Cup at the Spannabis 2008 Champions Cup.
– 2nd Hydro Cup at the 2007 Highlife Cup.
– 2nd Place Cannabis Cup at the High Times Cannabis Cup 2007.
– High Times Strain of the Year 2007

3. Jack Herer (55% sativa hybrid) 50-70day flowering time
Awards:
Jack Herer won the 2012 Lifetime Achievement Award at the HIGH TIMES Medical Cannabis Cup in Los Angeles

Additional strains there was constant demand for

1. Bay Eleven
2. Stonehenge
3. Sour Diesel
4. Train wreck
5. Time wreck
6. Grand Daddy Purp
7. Purple Haze
8. Super Silver Haze
9. White Widow

Info From Master Grower:
For future harvests, medicated markets are moving away from growing strains that have been indigenous to the west coast for some time. Their focus will be geared toward previous Cannabis Cup winner strains and uncommon imported strains. They will command a higher price from their dispensary partners. Medicated markets recognizes the importance memories play on smoking and will concentrate on growing strains that bring nostalgia to people’s lives. They have also been working on some patentable hybrid strains, which we would love to share once that process has progressed further along.

Additional Seed Bank (pending mothers)
1. Amnesia Haze
2. Big Bud
3. Blueberry Kush
4. Super Skunk
5. Gold Leaf
6. Green Crack

Medicated Markets delegation will depart Toronto at the end of current week, January 18th 2015 with Easton Pharmaceuticals hoping to announce a finalized agreement between the two parties; at that point or shortly thereafter. At which point Grow location addresses will also be provided to the public. There are a few minor details currently discussed including co-operation with Medicated Markets and use of its Grow expertise in Easton’s Port Perry, Ontario operations that are awaiting imminent MMPR Licensure. Pictures of this facility are to be found on Easton’s web site.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com

http://ecigmarkets.com/

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, and are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email:
info@eastonpharmaceuticalsinc.com

1 1476

Easton Pharmaceuticals Announces Signed Agreement With Medicated Markets International LLC, A Major California-Based Medical Marijuana Grower

TORONTO, ON–(Marketwired – Dec 31, 2014) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has signed an agreement with Medicated Markets International LLC., a major California medical marijuana grower.

Easton Pharmaceuticals has been in search of and intent on entering the lucrative Medical Marijuana cultivation and distribution industry via the acquisition of a grower via a direct investment or through a partial reverse merger / acquisition. Easton Management is pleased to announce that both Medicated Markets and Easton Pharmaceuticals have reached an agreement in principle. Easton had intended to announce the progress made prior to the Christmas holidays on December 23rd but the holiday season and the California companies prior commitments made this date not attainable. Information withheld within this release shall be mentioned and highlighted in subsequent releases upon finalization of a final executed agreement has been which shall provide shareholders with a detailed outline of a final agreement reached with “Medicated Markets International LLC.”

Medicated Market’s assets include: Two Nursery locations (20 acres) in the City of Perris, Riverside county and one main growing location in Mendocino County with a total actual growing area of approximately 3 acres. The Sites have a history of no less than three years of growing Medical Marijuana for resale to Dispensaries in the Los Angeles area. Affiliated farm names, the nursery locations including addresses are to be provided on the date of execution of a finalized agreement expected in January of 2015.

With the Letter of Intent executed and the majority of the conditions being checked off which included a company audit, proof of effective implementation of the GroZone technology through AMFIL Technologies, clarification on financing and a clear path to patient acquisitions in Canada having been demonstrated; current negotiations have now entered the advanced stages. A medicated markets delegation including having its master grower visiting with Easton management during the weekend of January 10th, will lead to an additional update including the total number of growing plants, strains, current dispensaries being serviced including names and addresses of those dispensaries and any other pertinent information. Easton is attempting to provide as much transparency as possible as history has demonstrated that most North American Grow operations within the Medical Marijuana Industry have for the most part been hesitant on not releasing too many details due to the fact medical marijuana has not yet been federally legalized although many states have moved forward with legalization.

The Medical Marijuana Movement in North America was started in California, which was the first state to establish a medical marijuana program, enacted by Proposition 215 in 1996 and Senate Bill 420 in 2003. Prop. 215, also known as the Compassionate Use Act, was approved by an initiative with a 55% majority, allowing people with cancer, AIDS and other chronic illnesses the right to grow or obtain marijuana for medical purposes when recommended by a doctor. SB 420, or the Medical Marijuana Protection Act, was signed into law by Governor Gray Davis and established an identification card system for medical marijuana patients. Marijuana advocates are hopeful that if they can get a legalization measure on the ballot in California in 2016, it will pass and federal reform will follow shortly afterwards.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

0 1269

Easton Pharmaceuticals Inc. Suspends All Potentially Dilutive Financing as a Direct Result of Negotiations With a Major California Based Medical Marijuana Grow-Op

TORONTO, ON–(Marketwired – Dec 22, 2014) – Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has suspended all types of financings considered more dilutionary compared to other financing options currently available.

This decision was made primarily as a result of negotiations Easton is having with a large medical marijuana grower who own multiple existing licenses and medical marijuana grow operations located in the state of California. Easton Management has requested that more transparency be provided to shareholders and investors than was previously the case with other previously announced medical marijuana initiatives. The California company has made certain demands of Easton including the recently announced audit of its financial statements, re-evaluation of its contractors, more detailed information regarding its Canadian medical marijuana initiative within the country of Canada, and to provide details and access to its joint venture relationship with AMFIL Technologies and their groZone system. The grower has implied availability of financing for the transactions at a premium to current market rates and that it be more in line with the 200 day moving average for the stock. The California Grower has also disclosed a high level of interest in becoming an equity stakeholder in Easton.

Easton anticipates making a formal announcement once some remaining minor details are sorted out. An exact timeline is subject to negotiations with another company.

The company has in the past year been conservative with how much cash it has expended into projects and has retained the majority of the $1,000,000 in financing obtained in 2014. The only circumstance where immediate additional cash would be required would be to execute on the Canadian medical marijuana grow operation. Easton has received a previous financing commitment exclusively towards this venture from a private accredited investor.

Market conditions and sentiment in the Medical Marijuana Sector are currently at a more depressed state compared to earlier in the spring of 2014. Easton’s current stock price is reflective of this market sentiment. Easton management has the responsibility to act in the best interests of the company and shareholders. Current market conditions do not necessitate a need to accept dilutive forms of financing at this point in time.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries including medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada for the country of Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

http://ecigmarkets.com/

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope,” “positive,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible,” or “intent to,” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
email:
info@eastonpharmaceuticalsinc.com

1 1288

Easton Pharmaceuticals Releases Preliminary Vaporizer Related Sales of $25,638.00 in the Month of November

NEW YORK, NY–(Marketwired – Dec 15, 2014) – Easton Pharmaceuticals (OTC PINK: EAPH) Is pleased to announce details on its Vaporizer units progress with sales of $25,638.00 for the month of November.

Month end inventory on hand was shown at $10,670.00 for its vaporizer unit. Vaporizers were not Easton’s primary goal when it entered into the Medical Marijuana Industry. However, the company has been able to leverage its vaporizer unit to negotiate with Legal Marijuana Prescription Services Businesses.

Its first sale of a Vaporizer was made on the first day of its website launch and was for a ZEDS vaporizer unit. Since that date sales have been progressing at a steady pace, Cyber week provided an additional catalyst for sales in November. Currently the most popular brands have been the following units:

http://ecigmarkets.com/product/hebe-2-0/

The HEBE 2.0 is a robust vaporizing instrument featuring an intuitive temperature control system. It offers a wide-mouth heating chamber for easy loading and cleaning and features a durable and rugged rubberized exterior.

http://ecigmarkets.com/product/davinci-vaporizer/

The DaVinci Vaporizer combines a feature rich platform with rugged portability. Our most popular model in the DaVinci line, which is offered in a very appealing and popular black matte finish.

The company believes it has already received a good return on its conservative investments made on its vaporizer Initiative. Future sales cannot be accurately estimated but testing has shown that Vaporizer retail Location(s) in the Greater Toronto Area along with a New York City location would both be viable initiatives. The company believes utilizing these retail locations as multi purpose facilities in the selling of products and services such as Vaporizers, OTC products, and a Marijuana Prescription Service would be successful. This could lead towards its ultimate goal of acquiring a database of Legal Canadian Medical Marijuana patients which the company has initiated discussion on. Monetizing of these patients could be made in two ways which would include subscription fee’s alongside an administrative fee it would charge any currently Licensed Providers.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and maintains an exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://www.ecigmarkets.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

0 1307

Easton Pharmaceuticals Executes Letter of Intent and Provides Details on Green Patient Network’s Business Plan

TORONTO, ON–(Marketwired – Dec 12, 2014) – Easton Pharmaceuticals (OTC: EAPH) announces it has executed a letter of intent with Canadian Medical Marijuana Club Inc and initiated negotiations to enter the Legal Medical Marijuana prescription access business.

Easton is negotiating a first of its kind in the Canadian medical marijuana industry by having Green Patient Network offered to the public. Green Patient Network should see synergies that present itself from Easton’s Vaporizer customers and the overlap in users which can directly help reduce current patient acquisition costs. Any prospective patient wishing to become a legal Canadian Medical Marijuana Card holder and member can find great value in the services offered by becoming a member of Medical Marijuana Club / Green Patient Network(GPN). Current Market targeted scope will include the major metro area’s in the Canadian marketplace (Vancouver, Calgary and Toronto). In march 2014 there were approximately 40,000 Legal Medical Marijuana Prescription holders in Canada. (Source Health Canada) Currently it is believed that number has increased to 60,000-70,000 patients. Growth in the patient population is being hampered as potential marijuana patients find it is still not an open acceptable subject to discuss their needs with their healthcare provider. Some MMPR un-informed doctors will not easily prescribe Medical Marijuana to their patients due to undue scrutiny placed on them by Health Canada, the RCMP and other regulators.

These underserved patients who suffer from Autism, Epilepsy, Dementia, Diabetes, Glaucoma, Tourette Syndrome, Cancer, PTSD and other ailments are in search of services such as the one being negotiated as a supplement to their current plan of care.

What the Green Patient Network Service Provides :

– Provides Canadian patients looking to obtain legal access with specialized online physician consultations via tele health.

– Connects underserved patients with a trusted network of doctors who advocate working with Licensed Providers within the framework of Canada’s MMPR network.

– Marijuana Licensed Provider prescription management and Marijuana batch number tracking services. This removes the stress of patients having to worry about losing their prescription or having to monitor if any recall’s are made by their LP provider.

– Nursing support line for any patients/ Members who have an adverse reaction to any Marijuana related product.

- Pre Qualification Questionnaire that helps make the entire process easy to understand for the patient.

Costs of this service: membership dues for a single are $375 annually or $150 initial and $30 each monthly subscription model.

Easton Pharmaceuticals Plans to provide updates on these fast moving negotiations in the Legal Medical Marijuana prescription access business within the next 7 to 15 days.. These negotiations are in no way detracting from other negotiations that are being done in the Medical Marijuana space in the United States or other business segments which we plan to divulge within the next week to 10 days.

In other news Easton Pharmaceuticals plans to update its shareholders on prior partnerships made and progress made with AMFIL Technologies and its GrowZone joint venture. Its current adoption has been proceeding well and revenue recognition is slated for this quarter on shipments made within the second Quarter of 2015.

In other news Easton and / or its representatives plans on attending the upcoming Emerald Cup.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

http://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

0 1324

Easton Pharmaceuticals Initiates Discussions With Canadian Medical Marijuana Association / Club

TORONTO, ON–(Marketwired – Dec 10, 2014) – Easton Pharmaceuticals (OTC: EAPH) announces it has started discussions with a Canadian Medical Marijuana Club.

Alongside its other business segments, Easton has been seeking acquisition targets in the areas of legal marijuana grow operations, patient access, patentable marijuana plant strains in the United States as well as Canada. As a result, Easton has initiated discussions with a Private Medical Marijuana Club, located in Toronto, Canada regarding a direct capital investment. This Club currently has a database of members as well as existing relationships with MMPR Licensed providers. The Marijuana club currently contains a database of members / patients with medical diagnosis and prescriptions who are able to match and provide patients with appropriate strains of Marijuana as well as match provider’s who might have those strains available for sale at the time. The club can be more efficient at contacting and informing any members if a batch is recalled providing a layer of safety to its members.

Easton Management believes that having access to patients will be the key to being successful in the Canadian Marketplace. Health Canada has taken a very draconian stance on MMPR’s and how they are allowed to market Marijuana as it’s scheduled as a narcotic in Canada.

Health Canada has issued warning letters to nearly every MMPR license holder towards their marketing practices.

“On November 25, 2014, Health Canada issued warning letters to 20 licensed producers regarding their advertising practices. These warning letters are in follow-up to an advertising bulletin sent to all licensed producers on June 30, 2014, that outlined the general prohibitions against the advertising of Cannabis contained in the Marihuana for Medical Purposes Regulations (MMPR), the Food and Drugs Act (FDA) and the Narcotic Control Regulations (NCR).

As a result of these prohibitions, the information provided by licensed producers to the public should be limited to basic information for prospective clients such as the brand name, proper or common name of the strain, the price per gram, the cannabinoid content, and the company’s contact information.

The licensed producers listed below have been given until January 12, 2015, to come into compliance with the advertising prohibitions following which, Health Canada will initiate appropriate enforcement action. Health Canada will update this list as licensed producers become compliant.

Clients should be aware that licensed producers who do not comply with the provisions in the FDA or the NCR can be subject to compliance and enforcement action, including suspension and possible revocation of the license or possible prosecution.”

http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/list-eng.php

Licensed producers for which Health Canada has issued warning letters

The companies listed have been issued warning letters and have until January 12, 2015, to come into compliance.

  • Bedrocan Canada Inc.
  • Broken Coast Cannabis Ltd.
  • CannMedica Pharma Inc.
  • CanniMed Inc.
  • Delta 9 Bio-Tech Inc.
  • In the Zone Produce Ltd.
  • MariCann Inc.
  • MedReleaf Corp.
  • Mettrum Ltd.
  • OrganiGram Inc.
  • Prairie Plant Systems Inc.
  • The Peace Naturals Project Inc.
  • ThunderBird Biomedical Inc.
  • Tilray
  • Tweed Inc.
  • Whistler Medical Marijuana Corp.

Additional Information on Easton Pharmaceuticals Inc can be found at

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

http://www.eastonpharmaceuticalsinc.com

https://finance.yahoo.com/q?s=eaph

https://twitter.com/eastonpharma

Safe Harbor

This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements